Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 7/20 | 0.50 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.50 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.50 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.50 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.50 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.50 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 3/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | PPARD | Q03181 | 7/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28227376 | 1.00 | HAO1 (0.61) | HAO1KMT2AMAPTCES2CES1 | |
| Hydrochloric Acid SCHEMBL5820401 | 1.00 | HAO1 (0.61) | HAO1KMT2AMAPTCES2CES1 | |
| Hydrochloric Acid SCHEMBL5480592 | 1.00 | HAO1 (0.61) | HAO1KMT2AMAPTCES2CES1 | |
| SCHEMBL1577191 | 0.98 | HAO1 (0.63) | HAO1KMT2AMAPTCES2CES1 | |
| Hydrochloric Acid SCHEMBL21174004 | 0.98 | HAO1 (0.57) | HAO1KMT2AMAPTCES2CES1 | |
| SCHEMBL184565 | 0.98 | HAO1 (0.63) | HAO1KMT2AMAPTCES2CES1 | |
| SCHEMBL671918 | 0.98 | HAO1 (0.63) | HAO1KMT2AMAPTCES2CES1 | |
| SCHEMBL3617938 | 0.98 | HAO1 (0.63) | HAO1KMT2AMAPTCES2CES1 | |
| SCHEMBL170019 | 0.98 | HAO1 (0.63) | HAO1KMT2AMAPTCES2CES1 | |
| SCHEMBL1121769 | 0.98 | HAO1 (0.63) | HAO1KMT2AMAPTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006000096-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC. (CA) | 2006-01-05 | — | — | WO | claimed |
| EP-4326721-A1 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | Protego Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117377777-A | Methods of diagnosing and treating subjects having a single nucleotide polymorphism at chromosome 2 locus 2:107,510,000-107,540,000 | 纽瑞姆制药（1991）有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-111943890-B | Pharmaceutical compounds | 艾欧米制药有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-112312904-A | Spiro compounds | C4医药公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-111943890-A | Pharmaceutical compounds | 艾欧米制药有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-107108556-B | Pharmaceutical compounds | 艾欧米制药有限公司 | 2020-09-29 | — | — | CN | disclosed |
| CN-107108556-A | Pharmaceutical compounds | 艾欧米制药有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-102317289-A | Lactams as beta secretase inhibitors | PFIZER | 2012-01-11 | — | — | CN | disclosed |
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| WO-2006000096-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC. (CA) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005023810-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC. (CA) | 2005-03-17 | — | — | WO | disclosed |
| CN-1549817-A | Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them | ��˹��ŵ�� | 2004-11-24 | — | — | CN | disclosed |
| EP-0684816-B1 | 5-HT2 RECEPTOR ANTAGONISTS FOR TREATING VENOUS CONDITIONS | SAM AMER & CO INC (US) | 2004-02-04 | — | — | EP | disclosed |
| US-5861416-A | TREATMENT OF ASTHMA OR COUGH | MERRELL PHARMACEUTICALS INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5824690-A | TREATING ASTHMA, COUGH | HOECHST MARION ROUSSEL INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5739336-A | SELECTIVE 5-HYDROXYTRYPTAMINE-2C RECEPTOR ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0684816-A1 | 5-HT 2? RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS | SAM AMER & CO., INC. (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0655449-A1 | A process for preparing N-( 2-pyrimidyl) piperazinyl butyl imides | JIN RO LIMITED (KR) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994018958-A1 | 5-HT2 RECEPTOR ANTAGONIST COMPOSITIONS USEFUL IN TREATING VENOUS CONDITIONS | SAM AMER & CO., INC. (US) | 1994-09-01 | — | — | WO | disclosed |